Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for treating primary and secondary osteoarthritis [1] Group 1: Product Approval - The approval of Glucosamine Sulfate Capsules enhances the company's formulation product portfolio [1] - This product is classified as a Category B item in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) [1] Group 2: Market Potential - The estimated sales revenue for Glucosamine Sulfate Capsules in Chinese public medical institutions is approximately RMB 850 million in 2024 [1] - The introduction of this product is expected to improve the company's overall competitiveness in the market [1] Group 3: Industry Considerations - The pharmaceutical sales business is subject to uncertainties influenced by industry policies and market conditions [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - The company has announced the receipt of a drug registration certificate for Glucosamine Sulfate Capsules [1] - The clinical application of the product focuses on treating osteoarthritis, indicating a strategic move into the growing market for joint health [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for treating primary and secondary osteoarthritis [1] Company Summary - The company submitted the application for the marketing authorization of Glucosamine Sulfate Capsules to the National Medical Products Administration in August 2024, and the application was accepted [1] - The drug received its registration certificate in February 2026, with the review conclusion being approval for registration [1] Industry Summary - Glucosamine Sulfate Capsules are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - The sales revenue for Glucosamine Sulfate Capsules in Chinese public medical institutions is estimated to be approximately RMB 850 million in 2024 [1]

智通财经APP讯，山东新华制药股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称"新 华制药"或"本公司")收到国家药品监督管理局核准签发的硫酸氨基葡萄糖胶囊(以下简称"本品")《药品 注册证书》。 本品属于《国家基本医疗保险、工伤保险和生育保险药品目录(2025年)》乙类品种。根据相关统计数 据，2024年中国公立医疗机构硫酸氨基葡萄糖胶囊销售额约为人民币8.5亿元。 2024年8月，新华制药向国家药品监督管理局药品审评中心(CDE)递交硫酸氨基葡萄糖胶囊上市许可注 册申报资料并获受理，2026年2月获得《药品注册证书》，审评结论为批准注册。本品临床主要用于治 疗塬发性及继发性骨关节炎。 ...

Group 1 - The State Council meeting on February 6 emphasized the need to innovate and improve policy measures to promote effective investment, focusing on major projects in infrastructure, urban renewal, public services, and emerging industries [8] - Eight departments, including the People's Bank of China, reiterated the prohibition of virtual currencies, emphasizing that they do not have the same legal status as fiat currencies and outlining clear policy requirements for stablecoins and tokenization of real-world assets [8] - On February 7, China successfully launched a reusable experimental spacecraft using the Long March 2F rocket, aimed at validating reusable spacecraft technology for peaceful space utilization [8] Group 2 - The People's Bank of China reported that as of January 2026, the country's gold reserves stood at 74.19 million ounces, marking a continuous increase for the 15th month [9] - The China Securities Regulatory Commission released a notice on February 6 regarding the selection direction for provincial-level research topics, focusing on enhancing the inclusiveness and adaptability of the capital market during the 14th Five-Year Plan period [9] - The Shanghai and Shenzhen Stock Exchanges revised and published regulatory guidelines for underwriting violations, aiming to enhance regulatory practices and ensure effective supervision [10] Group 3 - Longyun Co. will resume trading on February 9, planning to acquire 58% of Yuheng Film Industry [12] - Jihua Group will also resume trading on February 9, with plans for changes in its controlling shareholder and actual controller [12] - Xinwangda reached a settlement in a lawsuit involving over 2.3 billion yuan, while other companies like ST Pava and Aihua Long are facing legal challenges and investigations [12][12]

格隆汇2月6日丨新华制药(000756.SZ)公布，公司于2024年12月9日与NovoSana（Europe）B.V.（挪亚圣 诺（欧洲）公司）签订了《股权收购意向协议》("意向协议")，详情见2024年12月10日刊载于巨潮资讯 网相关公告。基于双方没有达成一致意见，根据协议终止条款，意向协议终止，其所涉及的所有条款均 终止履行。 ...

证券代码：000756 证券简称：新华制药 公告编号：2026-03 山东新华制药股份有限公司 关于终止《股权收购意向协议》的公告 三、对本公司的影响 意向协议仅系双方经友好协商达成的初步意向，未经公司董事会审议，双方未签署正式的股 权收购协议，本公司无需对意向协议终止承担任何责任。意向协议终止不会对公司的生产经营和 财务状况产生不利影响，不存在损害本公司和全体股东利益的情形。 特此公告。 山东新华制药股份有限公司董事会 2026 年 2 月 6 日 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 一、 交易概述 山东新华制药股份有限公司（"公司"）于 2024 年 12 月 9 日与 NovoSana（Europe）B.V. （挪亚圣诺（欧洲）公司）签订了《股权收购意向协议》("意向协议")，详情见 2024 年 12 月 10 日刊载于巨潮资讯网相关公告。 二、交易进展 基于双方没有达成一致意见，根据协议终止条款，意向协议终止，其所涉及的所有条款均终 止履行。 ...

新华制药公告，公司于2024年12月9日与NovoSana（Europe）B.V.签订的《股权收购意向协议》基于双 方未达成一致意见，根据协议终止条款，意向协议终止，所涉及的所有条款均终止履行。意向协议终止 不会对公司生产经营和财务状况产生不利影响，不存在损害公司和全体股东利益的情形。 ...

终止《股权收购意向协议》系本公司审慎研究后作出的决定，不会影响本公司现有生产经营活动，也不 会对本公司的发展造成不利影响，不存在损害本公司及全体股东，特别是中小股东利益的情形。 山东新华制药（000756）股份(00719)发布公告，有关本公司与挪亚圣诺(欧洲)公司签署《股权收购意向 协议》。股权收购意向协议仅系各方经友好协商达成的初步意向，然而，经进一步讨论及磋商后，订约 方未能就正式协议的条款及条件达成共识。本公司因此并无就该项目订立正式协议，该项目亦不会进 行。故此，本公司已决定终止该等股权收购意向协议。 ...

智通财经APP讯，山东新华制药股份(00719)发布公告，有关本公司与挪亚圣诺(欧洲)公司签署《股权收 购意向协议》。股权收购意向协议仅系各方经友好协商达成的初步意向，然而，经进一步讨论及磋商 后，订约方未能就正式协议的条款及条件达成共识。本公司因此并无就该项目订立正式协议，该项目亦 不会进行。故此，本公司已决定终止该等股权收购意向协议。 终止《股权收购意向协议》系本公司审慎研究后作出的决定，不会影响本公司现有生产经营活动，也不 会对本公司的发展造成不利影响，不存在损害本公司及全体股东，特别是中小股东利益的情形。 ...